As of December 31, 2019, GIBH has undertaken more than 1,220 scientific research projects of the Ministry of Science and Technology of the People’s Republic of China, the Chinese Academy of Sciences, the National Natural Science Foundation of China, and local governments; moreover, it has published 1,608 scientific papers including 1,450 SCI papers, and submitted 662 patent applications, of which there is 503 domestic patents, 99 international patents and 60 PCT applications. The total number of granted applications is 302, including 272 domestic patents and 30 international ones. The invention patent "A method for establishing a model of immunodeficiency mouse" won the 19th China Patent Excellence Award and the 4th Guangdong Patent Excellence Award; the invention patent "Integrative plasmid pOPHI and resistance screening marker-free self-luminescent mycobacterium" won the 5th Guangdong Patent Excellence Award. In total, GIBH has won 2 second prizes of National Natural Science Award, 1 Outstanding Science and Technology Achievement Prize of Chinese Academy of Sciences, 1 Nanyue Innovation Award, 3 first prizes of Guangdong Science and Technology Award, 3 first prizes of Guangzhou Science and Technology Award, 1 China Patent Excellence Award and 2 Guangdong Patent Excellence Awards.
In recent years, GIBH has achieved a number of vital scientific research results—outstanding achievements in the development of anti-leukemia drugs, anti-malarial drugs, anti-senile dementia and anti-neuroinflammation drugs, and anti-lung cancer drugs. Thereinto, GZD824, a Bcr-AblT315I inhibitor used for the treatment of drug-resistant chronic myeloid leukemia, has obtained the clinical approval of Type 1.1 new drugs and has completed the clinical phase II study; the anti-senile dementia drug candidate GIBH-130 (AD16) has obtained the clinical approval of Type 1.1 new drugs and has started the clinical phase I study; the anti-tumor new drug ASK120067 has obtained the clinical approval of Type 1.1 drugs, has completed the clinical Phase II study, and is going to start the Phase III study. In the field of stem cells, numerous world-renowned achievements, like “A discovery of vitamin C can enhance the efficiency of inducing multipotent stem cells and its epigenetic regulatory mechanism; inducing multipotent stem cells is driven by mesenchymal-epithelial transition mechanism and built by the ultra-high-speed inducing system”, have created opportunities for prospective development of regenerative medicine based on stem cells as a basic therapeutic approach. In terms of large animal models, over 70 genetically modified pigs of important application value for biomedicine have been obtained, ranking first in the world. It has also made some achievements in the fields of tracing for influenza virus, new vaccine development, copper catalysis, and synthesis of bioactive molecular, etc.. Meanwhile, in order to reducing China’s dependence on scientific research instruments and equipment imports, a range of scientific equipment with independent intellectual property rights, which can be used for industrialization production for our own scientific research purpose, have been developed.